Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial
Abstract Background Mild cognitive impairment (MCI) is considered an intermediate phase between normal aging and dementia. As the majority of cases of amnestic MCI (aMCI) progress to Alzheimer’s disease (AD), it is considered the prodromal stage of AD, and a treatment target for prevention of furthe...
Main Authors: | Hee-Yeon Shin, Ha-Ri Kim, Geon-Ho Jahng, Chul Jin, Seungwon Kwon, Seung-Yeon Cho, Seong-Uk Park, Woo-Sang Jung, Sang-Kwan Moon, Chang-Nam Ko, Jung-Mi Park |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-10-01
|
Series: | BMC Complementary Medicine and Therapies |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12906-021-03428-6 |
Similar Items
-
Effects of Kami Guibi-tang in patients with mild cognitive impairment: study protocol for a phase III, randomized, double-blind, and placebo-controlled trial
by: Hee-Yeon Shin, et al.
Published: (2022-12-01) -
The effectiveness of Kami Guibi-tang for cognitive impairment patients: A retrospective chart review
by: Tae-Bin Yim, et al.
Published: (2024-01-01) -
The effectiveness and safety of Kami Guibi-tang for mild cognitive impairment: study protocol of a pilot, randomized, placebo-controlled, double-blind trial
by: Hee-Yeon Shin, et al.
Published: (2019-07-01) -
Effect of Kami Guibi-tang (KGT) in elderly subjects with insomnia: a study protocol from a single center, randomized, double-blind, placebo-controlled trial
by: Kyeong-Hwa Lee, et al.
Published: (2023-10-01) -
Electroencephalography-based classification of Alzheimer’s disease spectrum during computer-based cognitive testing
by: Seul-Kee Kim, et al.
Published: (2024-03-01)